<html>
<head>
<title>Section 318:16-a Standards for Collaborative Pharmacy Practice.</title>
<!-- Hide metadata
<titlename>TITLE XXX OCCUPATIONS AND PROFESSIONS</titlename>
<chapter>CHAPTER 318 PHARMACISTS AND PHARMACIES</chapter>
<sectiontitle>Section 318:16-a Standards for Collaborative Pharmacy Practice.</sectiontitle>
-->
<meta name="titlename" content="TITLE XXX OCCUPATIONS AND PROFESSIONS">
<meta name="chapter" content="CHAPTER 318 PHARMACISTS AND PHARMACIES">
<meta name="sectiontitle" content="Section 318:16-a Standards for Collaborative Pharmacy Practice.">
<meta name="sourcenote" content="Source.  2006, 164:6, eff. July 23, 2006.">
<meta name="codesect" content="<br>&nbsp&nbsp&nbspI. For a pharmacist to participate in a collaborative pharmacy practice agreement, the pharmacist shall:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) Hold an unrestricted and current license to practice as a pharmacist in New Hampshire.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) Have at least $1,000,000 of professional liability insurance coverage.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(c) Have earned a Pharm.D. degree or completed 3 years of institutional clinical experience as a licensed pharmacist.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(d) Complete at least 5 contact hours or 0.5 continuing education units of board-approved continuing education each year.  Such continuing education shall address the area or areas of practice generally related to the collaborative pharmacy practice agreement or agreements.  The continuing education hours may be applied to the requirements for licensure as a pharmacist in this state.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(e) In order to administer drugs by injection, have completed training that includes programs approved by the Accreditation Council for Pharmacy Education (ACPE) or curriculum-based programs from an ACPE-accredited college of pharmacy or state or local health department programs or programs recognized by the board.<br>&nbsp&nbsp&nbspII. Collaborative pharmacy practice agreements shall meet the following general requirements:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) Each protocol developed, pursuant to the collaborative pharmacy practice agreement, shall contain detailed direction concerning the services that the pharmacist may perform for that patient.  The protocol shall include, but not be limited to:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(1) The specific drug or drugs to be managed by the pharmacist.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(2) The terms and conditions under which drug therapy may be implemented, modified, or discontinued.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(3) The conditions and events upon which the pharmacist is required to notify the collaborating practitioner.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(4) The laboratory tests that may be ordered in accordance with medication therapy management.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(5) In instances where drug therapy is discontinued, the pharmacist shall notify the collaborating practitioner of such discontinuance in the time-frame and manner established by the collaborative pharmacy practice agreement.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(6) All activities performed by the pharmacist in conjunction with the protocol shall be documented as specified in the protocol.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) The collaborative pharmacy practice agreement and protocols shall be on file at the pharmacist's place of practice.  The collaborative pharmacy practice agreement and protocols shall be available to the appropriate licensing board for review upon request.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(c) Collaborative pharmacy practice agreements shall be reviewed, at least every 2 years, by both the pharmacist and the practitioner, and may be terminated, in writing, by either party.  When collaborative pharmacy practice agreements are terminated, the patient shall be informed and provided with details to allow for the uninterrupted continuation of his or her medication therapy management regimen.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(d) Neither the attending practitioner nor the pharmacist in a collaborative practice agreement may seek to gain personal financial benefit by participating in any incentive-based program that influences or encourages therapeutic or product changes or the ordering of tests or services.<br>&nbsp&nbsp&nbspIII. A collaborative pharmacy practice agreement that complies with all the requirements of this section shall only be allowed in the following settings:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) Hospitals.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) Long-term care facilities.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(c) Licensed inpatient or outpatient hospice settings.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(d) Ambulatory care clinics with onsite supervision by the attending practitioner and with a collaborating pharmacist who has no connection to any onsite retail pharmacy.">
</head>
<body>
<center><h1>TITLE XXX<br>OCCUPATIONS AND PROFESSIONS</h1></center>
<center><h2>CHAPTER 318<br>PHARMACISTS AND PHARMACIES</h2></center>
<center><h2>Licensed Pharmacists</h2></center>
<center><h3>Section 318:16-a</h3></center>
&nbsp;&nbsp;&nbsp;<b> 318:16-a Standards for Collaborative Pharmacy Practice. &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
I. For a pharmacist to participate in a collaborative pharmacy practice agreement, the pharmacist shall:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Hold an unrestricted and current license to practice as a pharmacist in New Hampshire.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Have at least $1,000,000 of professional liability insurance coverage.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) Have earned a Pharm.D. degree or completed 3 years of institutional clinical experience as a licensed pharmacist.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) Complete at least 5 contact hours or 0.5 continuing education units of board-approved continuing education each year.  Such continuing education shall address the area or areas of practice generally related to the collaborative pharmacy practice agreement or agreements.  The continuing education hours may be applied to the requirements for licensure as a pharmacist in this state.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(e) In order to administer drugs by injection, have completed training that includes programs approved by the Accreditation Council for Pharmacy Education (ACPE) or curriculum-based programs from an ACPE-accredited college of pharmacy or state or local health department programs or programs recognized by the board.
<br>
&nbsp&nbsp&nbsp
II. Collaborative pharmacy practice agreements shall meet the following general requirements:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Each protocol developed, pursuant to the collaborative pharmacy practice agreement, shall contain detailed direction concerning the services that the pharmacist may perform for that patient.  The protocol shall include, but not be limited to:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(1) The specific drug or drugs to be managed by the pharmacist.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(2) The terms and conditions under which drug therapy may be implemented, modified, or discontinued.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(3) The conditions and events upon which the pharmacist is required to notify the collaborating practitioner.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(4) The laboratory tests that may be ordered in accordance with medication therapy management.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(5) In instances where drug therapy is discontinued, the pharmacist shall notify the collaborating practitioner of such discontinuance in the time-frame and manner established by the collaborative pharmacy practice agreement.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(6) All activities performed by the pharmacist in conjunction with the protocol shall be documented as specified in the protocol.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) The collaborative pharmacy practice agreement and protocols shall be on file at the pharmacist's place of practice.  The collaborative pharmacy practice agreement and protocols shall be available to the appropriate licensing board for review upon request.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) Collaborative pharmacy practice agreements shall be reviewed, at least every 2 years, by both the pharmacist and the practitioner, and may be terminated, in writing, by either party.  When collaborative pharmacy practice agreements are terminated, the patient shall be informed and provided with details to allow for the uninterrupted continuation of his or her medication therapy management regimen.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) Neither the attending practitioner nor the pharmacist in a collaborative practice agreement may seek to gain personal financial benefit by participating in any incentive-based program that influences or encourages therapeutic or product changes or the ordering of tests or services.
<br>
&nbsp&nbsp&nbsp
III. A collaborative pharmacy practice agreement that complies with all the requirements of this section shall only be allowed in the following settings:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Hospitals.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Long-term care facilities.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(c) Licensed inpatient or outpatient hospice settings.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(d) Ambulatory care clinics with onsite supervision by the attending practitioner and with a collaborating pharmacist who has no connection to any onsite retail pharmacy.
</codesect>
<sourcenote>
<p><b>Source.</b>  2006, 164:6, eff. July 23, 2006.</p>
</sourcenote>
</body>
</html>
